Q-omics provides the consensus-scored TNFRSF10B profile across patient tissues and cancer cell-line models. TNFRSF10B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TNFRSF10B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TNFRSF10B RNA expression shows 19,625 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where TNFRSF10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF10B survival associations across molecular data types. TNFRSF10B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF10B RNA expression–survival associations across cancer types. High TNFRSF10B expression shows unfavorable associations in MESO, ACC, LGG, KIRC, LUSC and PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TNFRSF10B RNA expression.
This table summarizes TNFRSF10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TNFRSF10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF10B shows higher tumor expression in KIRC, KIRP, HNSC, COAD, THCA and STAD. The KIRC box plot shows higher TNFRSF10B RNA expression in tumor versus normal tissue (log2 FC = +1.502, t-test p < 0.001).
This table shows molecular features associated with TNFRSF10B in patient tissues and cancer cell lines. In patient samples, TNFRSF10B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF10B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
